2011 recommendations for the diagnosis and management of gout and hyperuricemia (Q34250995)

31 July 2017

title

2011 recommendations for the diagnosis and management of gout and hyperuricemia (English)

1 reference

31 July 2017

13

Didier A Mandelbrot

1 reference

31 July 2017

22

N Lawrence Edwards

1 reference

31 July 2017

Max Hamburger

1

1 reference

31 July 2017

Herbert S B Baraf

2

1 reference

31 July 2017

Thomas C Adamson

3

1 reference

31 July 2017

Jan Basile

4

1 reference

31 July 2017

Lewis Bass

5

1 reference

31 July 2017

Brent Cole

6

1 reference

31 July 2017

Paul P Doghramji

7

1 reference

31 July 2017

Germano A Guadagnoli

8

1 reference

31 July 2017

Frances Hamburger

9

1 reference

31 July 2017

Regine Harford

10

1 reference

31 July 2017

Joseph A Lieberman

11

1 reference

31 July 2017

David R Mandel

12

1 reference

31 July 2017

Bonny P McClain

14

1 reference

31 July 2017

Eric Mizuno

15

1 reference

31 July 2017

Allan H Morton

16

1 reference

31 July 2017

David B Mount

17

1 reference

31 July 2017

Richard S Pope

18

1 reference

31 July 2017

Kenneth G Rosenthal

19

1 reference

31 July 2017

Katy Setoodeh

20

1 reference

31 July 2017

John L Skosey

21

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

The Physician and Sportsmedicine

31 July 2017

published in

1 reference

31 July 2017

volume

39

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

98-123

1 reference

Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Quality of care for gout in the US needs improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Opportunities for improving medication use and monitoring in gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Prescription and comorbidity screening following consultation for acute gout in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Adherence with urate-lowering therapies for the treatment of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Health care utilization in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Going from evidence to recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Grading quality of evidence and strength of recommendations for diagnostic tests and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

"Clinical features of women with gout arthritis." A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

CHANGES IN SERUM AND URINARY URIC ACID WITH THE DEVELOPMENT OF SYMPTOMATIC GOUT

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Uromodulin mutations causing familial juvenile hyperuricaemic nephropathy lead to protein maturation defects and retention in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Frequency and risk factors of gout flares in a large population-based cohort of incident gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Menopause, postmenopausal hormone use and risk of incident gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Comparison of drug adherence rates among patients with seven different medical conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Plasma uric acid level and risk for incident hypertension among men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Hyperuricemia and incidence of hypertension among men without metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Uric acid and the development of hypertension: the normative aging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Hyperuricemia and risk of stroke: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Long-term cardiovascular mortality among middle-aged men with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Gout: an independent risk factor for all-cause and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

High serum uric acid as a novel risk factor for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum uric acid and components of the metabolic syndrome in non-diabetic populations in Mauritian Indians and Creoles and in Chinese in Qingdao, China

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

The prevalence of metabolic syndrome in patients with gout: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Elevated uric acid increases the risk for kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Predictors of new-onset decline in kidney function in a general middle-european population.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Colchicine poisoning: the dark side of an ancient drug

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

21 January 2018

Colchicine update: 2008.

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Potentially fatal interaction between colchicine and disulfiram.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Acute myopathy in a patient with concomitant use of pravastatin and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

The effect of serum urate on gout flares and their associated costs: an administrative claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum urate levels and gout flares: analysis from managed care data

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Treating to target: a strategy to cure gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Update on gout: new therapeutic strategies and options

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Gout. Novel therapies for treatment of gout and hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Quality of life and disability in patients with treatment-failure gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum urate during acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Metabolic syndrome characteristics in gout patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

The prevalence of rheumatic diseases in central Greece: a population survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

A prescription for lifestyle change in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Serum uric acid and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Plasma urate and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Prevalence of contraindications and prescription of pharmacologic therapies for gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Effect of fenofibrate on uric acid metabolism and urate transporter 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

A Diagnostic Rule for Acute Gouty Arthritis in Primary Care Without Joint Fluid Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

Adherence to Urate-Lowering Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPSM.2011.11.1946

21 January 2018

Identifiers

DOI

10.3810/PSM.2011.11.1946

1 reference

31 July 2017

1 reference